Some older studies have evaluated NAD+ at high doses (1-2g daily) for conditions such as chronic schizophrenia, but no improvement was noted in these studies.3 This may be because NAD+ is expected to have poor oral bioavailability.12 For this reason, when trying to boost NAD+ levels using an oral route, precursors such as nicotinamide or nicotinamide mononucleotide are typically used instead of NAD+
[ [PMID: 33185364] [ [PMID: 33972770] [ [PMID: 34131333] et al
Association between receptors and portal hypertension in cirrhosis (treatment strategies and mechanisms) Application of beta blockers in the treatment of portal hypertension (clinical research evidence) Portal hypertension is a major feature of cirrhosis, which can lead to other serious complications, such as liver cancer, hepatopulmonary syndrome, and hepatorenal syndrome 73
Her interests include emerging medical research, exercise, nutrition, mental health, and maternal and pediat...